Resource Center
Resource Center
A study in Myanmar published by CHAI and FIND in PLOS shows that integrated HCV and HIV testing on a single platform is feasible, and does not
Read moreA study published by Cornell University and Clinton Health Access Initiative shows that pharmaceutical companies could cut by nearly half their carbon footprint if they optimized processes and used renewable energy sources
Read moreCHAI is calling for new investments and additional research to understand the unique circumstances of children with advanced HIV disease.
Read moreHealth experts from the HIV Modelling Consortium, University College London, World Health Organization, and CHAI, among other organizations have published a modeling study that shows that long-acting injectable cabotegravir has the potential to significantly reduce new HIV infections
Read moreCHAI in partnership with Infectious Diseases Institute (IDI) through the Unitaid-CHAI AHD Initiative Enhanced Partner Network has developed an open access mobile application for healthcare workers to support the rollout of the World Health Organization (WHO) recommended package of care for people with Advanced HIV Disease.
Read moreThis webinar, recorded Dec. 8, 2022, highlights key trends in CHAI’s annual HIV Market Report, which provides a detailed look at the complex, ever-changing HIV commodity markets in low- and middle-income countries based on aggregated market intelligence from our work in over 20 countries.
Read moreWorld AIDS Day 2022 is an opportunity to celebrate achievements in the fight against HIV – and reflect on how far we still have to go. This year’s theme, Equalize, highlights the critical need to address inequalities that are limiting progress. At CHAI, we are working to close these equity gaps in 2022 and beyond....
Read moreCHAI's 2021 Annual Report is out now. In it, we recognize the incredible efforts of our staff during a difficult year.
Read moreCHAI has released the 13th issue of our annual HIV market report detailing the complex, ever-changing HIV commodity markets in low- and middle-income countries based on aggregated market intelligence from our work in over 20 countries.
Read moreAs part of a growing portfolio of biomedical HIV prevention options, long-acting injectable cabotegravir (CAB-LA) was approved by the US FDA in December 2021. Evidence from two clinical trials, HPTN 083 and HPTN 084, which enrolled nearly 8,000 participants across 13 countries (including 7 countries in sub-Saharan Africa), demonstrated that CAB-LA is safe and highly...
Read more